Cryo-Cell International, Inc. cash flow statement CCEL

Annual Quarterly

In fiscal 2025, which ended Nov 30, 2025, Cryo-Cell International, Inc. generated $5.5 million of cash from operations, down 8.9% from the year before. It spent $230,475 on capital expenditures. That left free cash flow of $5.2 million. The company returned $3.2 million in dividends and $169,502 in share buybacks to shareholders.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

Line	FY 2026 Aug 31, 2026	FY 2025 Nov 30, 2025	FY 2024 Nov 30, 2024	FY 2023 Nov 30, 2023	FY 2022 Nov 30, 2022	FY 2021 Nov 30, 2021	FY 2020 Nov 30, 2020	FY 2019 Nov 30, 2019	FY 2018 Nov 30, 2018	FY 2013 Nov 30, 2013	FY 2012 Nov 30, 2012
Operating
Depreciation and amortization	1 -2.0%	1 +42.0%	1 -50.4%	1 -6.6%	1 +44.2%	1 +179.1%	0 -7.2%	0 +122.6%	0 +37.0%	0 -7.8%	0 -43.5%
Stock-based compensation	0 -31.5%	0 -46.6%	1 -4.3%	1 +77.0%	0 +53.0%	0 -51.5%	1 +56.4%	0 -16.9%	0 -50.8%	0 -79.5%	1 +302.8%
Operating cash flow	5 -22.6%	5 -8.9%	6 -32.6%	9 +4.0%	9 +8.2%	8 -6.4%	8 +34.5%	6 +18.0%	5	1 +127.8%	0 -55.9%
Investing
Capital expenditures	0 +56.7%	0 -90.4%	2 -64.9%	7 -43.8%	12 +563.5%	2 +1734.7%	0 -84.9%	1 +48.4%	0 +353.7%	0 +161.9%	0 -73.6%
Investing cash flow	-0 +76.9%	-1 +80.0%	-5 +40.1%	-8 +46.7%	-15 -119.8%	-7 -2044.5%	0 +154.0%	-1 +94.1%	-11	1 +19.4%	1 +132.5%
Financing
Dividends paid	0	3 +59.9%	2	0 -100.0%	8	—	—	—	—	—	—
Stock buybacks	0 -100.0%	0 -88.1%	1 +78.2%	1 -56.1%	2 +629.8%	0 -74.9%	—	1 +122.2%	—	1 -56.6%	2
Financing cash flow	-3 +25.5%	-5 -384.6%	-1 +52.8%	-2 -1501.9%	0 +104.8%	-3 +38.6%	-5 +2.5%	-5 -189.9%	6	-1 +85.4%	-5 -6217.1%
Change in cash
Free cash flow	5 -24.8%	5 +45.5%	4 +73.4%	2 +157.9%	-4 -159.0%	6 -27.2%	8 +48.5%	6 +15.3%	5	0 +107.7%	0 -27.5%
Per share
Free cash flow per share	0.58 -23.7%	0.65 +48.1%	0.44 +76.1%	0.25 +158.9%	-0.42 -158.2%	0.73 -29.1%	1.03 +53.5%	0.67 +2.2%	0.65	0.04 +114.1%	0.02 -24.5%
Dividend per share	—	—	0.25 -72.2%	0.90	—	—	—	—	—	—	—
Shareholder returns
Returned to shareholders	0	3	3	1	9	0	—	1	—	1	2
Share of free cash flow	0.00%	64.80%	95.49%	38.40%	—	4.09%	—	17.62%	—	156.42%	749.01%
Ratios
Free cash flow margin	14.94%	16.63%	11.28%	6.64%	-11.85%	21.09%	26.86%	17.70%	16.73%	2.49%	1.27%
Capital expenditures to revenue	0.86%	0.73%	7.51%	21.82%	40.11%	6.35%	0.32%	2.08%	1.53%	1.84%	0.74%
Stock-based compensation to revenue	1.15%	1.32%	2.44%	2.61%	1.52%	1.04%	2.00%	1.25%	1.64%	1.43%	7.37%
Cash conversion	—	—	14.95x	—	3.09x	3.80x	2.34x	2.75x	—	29.96x	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry: Services-Misc Health & Allied Services, NEC (SIC 8090)
Listed as: CCEL (NYSE)
Fiscal year ends: November 30
Incorporated in: DE
Headquarters: Oldsmar, FL
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 862692
Former names: CRYO CELL INTERNATIONAL INC (until Oct 28, 2026)

Other Services-Misc Health & Allied Services, NEC companies

All 15 Services-Misc Health & Allied Services, NEC companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.